These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27956420)

  • 21. Computational Modeling of Antiviral Drug Diffusion from Poly(lactic- co-glycolic-acid) Fibers and Multicompartment Pharmacokinetics for Application to the Female Reproductive Tract.
    Halwes ME; Tyo KM; Steinbach-Rankins JM; Frieboes HB
    Mol Pharm; 2018 Apr; 15(4):1534-1547. PubMed ID: 29481088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
    Keller MJ; Mesquita PM; Marzinke MA; Teller R; Espinoza L; Atrio JM; Lo Y; Frank B; Srinivasan S; Fredricks DN; Rabe L; Anderson PL; Hendrix CW; Kiser PF; Herold BC
    AIDS; 2016 Mar; 30(5):743-51. PubMed ID: 26605514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel.
    Herold BC; Chen BA; Salata RA; Marzinke MA; Kelly CW; Dezzutti CS; McGowan I; Galaska B; Levy L; Piper JM; Hillier S; Hendrix CW
    Clin Infect Dis; 2016 Feb; 62(3):375-382. PubMed ID: 26508513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atazanavir exposure is effective during pregnancy regardless of tenofovir use.
    Colbers A; Hawkins D; Hidalgo-Tenorio C; van der Ende M; Gingelmaier A; Weizsäcker K; Kabeya K; Taylor G; Rockstroh J; Lambert J; Moltó J; Wyen C; Sadiq ST; Ivanovic J; Giaquinto C; Burger D;
    Antivir Ther; 2015; 20(1):57-64. PubMed ID: 24992294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen.
    Imaz A; Martinez-Picado J; Niubó J; Kashuba AD; Ferrer E; Ouchi D; Sykes C; Rozas N; Acerete L; Curto J; Vila A; Podzamczer D
    J Infect Dis; 2016 Nov; 214(10):1512-1519. PubMed ID: 27578849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients.
    Punyawudho B; Thammajaruk N; Thongpeang P; Matthews G; Lewin SR; Burger D; Ruxrungtham K; Avihingsanon A
    Int J Clin Pharmacol Ther; 2015 Nov; 53(11):947-54. PubMed ID: 26308175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.
    Seifert SM; Chen X; Meditz AL; Castillo-Mancilla JR; Gardner EM; Predhomme JA; Clayton C; Austin G; Palmer BE; Zheng JH; Klein B; Kerr BJ; Guida LA; Rower C; Rower JE; Kiser JJ; Bushman LR; MaWhinney S; Anderson PL
    AIDS Res Hum Retroviruses; 2016; 32(10-11):981-991. PubMed ID: 27526873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods.
    Lu Y; Goti V; Chaturvedula A; Haberer JE; Fossler MJ; Sale ME; Bangsberg D; Baeten JM; Celum CL; Hendrix CW
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5379-86. PubMed ID: 27353269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.
    Margot NA; Liu Y; Miller MD; Callebaut C
    Antiviral Res; 2016 Aug; 132():50-8. PubMed ID: 27208653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850).
    Pereira AS; Smeaton LM; Gerber JG; Acosta EP; Snyder S; Fiscus SA; Tidwell RR; Gulick RM; Murphy RL; Eron JJ
    J Infect Dis; 2002 Jul; 186(2):198-204. PubMed ID: 12134255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques.
    Daly MB; Sterling M; Holder A; Dinh C; Nishiura K; Khalil G; García-Lerma JG; Dobard C
    Antiviral Res; 2021 Feb; 186():105001. PubMed ID: 33385420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women.
    Benaboud S; Hirt D; Launay O; Pannier E; Firtion G; Rey E; Bouazza N; Foissac F; Chappuy H; Urien S; Tréluyer JM
    Antimicrob Agents Chemother; 2012 Feb; 56(2):857-62. PubMed ID: 22123690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.
    Vera JH; Jackson A; Dickinson L; Else L; Barber T; Mora-Peris B; Back D; Boffito M; Winston A
    HIV Clin Trials; 2015; 16(1):39-42. PubMed ID: 25777188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tenofovir Inhibits Wound Healing of Epithelial Cells and Fibroblasts from the Upper and Lower Human Female Reproductive Tract.
    Rodriguez-Garcia M; Patel MV; Shen Z; Bodwell J; Rossoll RM; Wira CR
    Sci Rep; 2017 Apr; 8():45725. PubMed ID: 28368028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men.
    Dumond JB; Reddy YS; Troiani L; Rodriguez JF; Bridges AS; Fiscus SA; Yuen GJ; Cohen MS; Kashuba AD
    J Acquir Immune Defic Syndr; 2008 Jun; 48(2):156-62. PubMed ID: 18360288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen.
    Greene SA; Chen J; Prince HMA; Sykes C; Schauer AP; Blake K; Nelson JAE; Gay CL; Cohen MS; Dumond JB
    Clin Pharmacol Ther; 2019 Oct; 106(4):821-830. PubMed ID: 31002391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding the molecular mechanism of sequence dependent tenofovir removal by HIV-1 reverse transcriptase: differences in primer binding site versus polypurine tract.
    Iyidogan P; Anderson KS
    Antiviral Res; 2012 Aug; 95(2):93-103. PubMed ID: 22664235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV.
    Baxi SM; Scherzer R; Greenblatt RM; Minkoff H; Sharma A; Cohen M; Young MA; Abraham AG; Shlipak MG;
    AIDS; 2016 Feb; 30(4):609-18. PubMed ID: 26558723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.
    Ghosn J; Chaix ML; Peytavin G; Bresson JL; Galimand J; Girard PM; Raffi F; Cohen-Codar I; Delfraissy JF; Rouzioux C
    J Antimicrob Chemother; 2008 Jun; 61(6):1344-7. PubMed ID: 18343806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles.
    Cobb DA; Smith N; Deodhar S; Bade AN; Gautam N; Shetty BLD; McMillan J; Alnouti Y; Cohen SM; Gendelman HE; Edagwa B
    Nat Commun; 2021 Sep; 12(1):5458. PubMed ID: 34531390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.